Papers: 10.3389/fsurg.2020.00059

https://doi.org/10.3389/fsurg.2020.00059

The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas

Cited by: 4
Author(s): M. R. Chambers, R. Timothy Bentley, David K. Crossman, Jeremy B. Foote, Jey W. Koehler, James M. Markert, Nidal B. Omar, Simon Platt, D. Mitchell Self, Andy Shores, Donald C. Sorjonen, Alicia M. Waters, Amy B. Yanke, G. Yancey Gillespie
Published: about 6 years ago

Software Mentions 3